Minerva Neurosciences tanks (NERV -81.4%) after the company announces disappointing results from Phase 3 clinical trial evaluating roluperidone (MIN-101) in adults with negative symptoms of schizophrenia
The study failed to beat placebo as measured by the change from baseline in a scale called NSFS at week 12.
The company says that it intends to consult with
the FDA about the next steps in the development of roluperidone after
the completing the analysis of the study data.
https://seekingalpha.com/news/3578711-minervasminus-81-roluperidone-flunks-schizophrenia-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.